The use of albumin-containing solutions in critically ill patients has been recently revisited, following evidence on harmful effects of synthetic colloids, and novel randomized controlled trials (RCTs) in sepsis. Here, we review the most recent findings on albumin administration in acutely ill and septic patients.
INTRODUCTION
In humans, albumin is the colloid molecule most representative in the extracellular space, being crucial in regulating the physiology of microvascular fluid dynamics [1] . Moreover, albumin, being one of the molecules synthesized by the liver with the highest energy requirement, acts as an important player of several secondary functions, including transportation of endogenous and exogenous molecules, antioxidant and anti-inflammatory properties [2, 3] . This is why its use as intravenous solution has been widely applied to critically ill patients, until the publication of a highly ranking metaanalysis in 1998 has warned against its use [4] . As the history of medicine goes on, and more solid evidence becomes available, the publication of the SAFE trial has finally clarified its potential disadvantages [5] and advantages [6] in specific categories of critically ill patients, while assuring its safety in the heterogeneous population [7] . Recently, an increasing attention to the use of albumin-containing solutions in patients admitted to intensive care units (ICUs) has resumed, mainly for two reasons: first, the evidences that most of the available synthetic colloids may be harmful in critically ill patients [8] [9] [10] ; second, the conclusions of large randomized controlled trials (RCTs) on the use of albumin in severe sepsis [11,12 && ]. In the current manuscript, we would like to review the recent findings related to the physiological rationale of using albumin in critically ill patients, and the last evidence available on its clinical impact.
ALBUMIN AND VASCULAR COLLOID AND OSMOTIC PRESSURE
Oncotic properties characterizing the intravascular space depend on the concentration of albumin in the capillaries, in which the membrane separating intravascular and extravascular spaces is impermeable to solutes (mainly albumin) and permeable to the solvent (water) [13] . Normal concentration of albumin, in humans, equals 35-55 g/l [3] , corresponding to about 0.54-0.85 mmol/l. The osmotic pressure because of a solute equals the pressure that the solute would exert if present in gas-phase with the same number of particles occupying the same volume the solution occupies. Therefore, 0.54 mmol of albumin would exert a pressure of 9.2 mmHg. In fact, as 1 mmol occupies about 22.4 ml at 760 mmHg, 0.54 mmol will occupy 12.1 ml. Since according to the Boyle's law, if the temperature is constant, the 'pressure-time-volume' product for a constant amount of gas is constant [14] , 12.1 ml of albumin in 'gas-phase' will exert a pressure equal to 12.1 ml Â 760 mmHg ¼ 9196 ml Â mmHg, which, in 1-l solution will equal 9.2 mmHg. Indeed, if the oncotic pressure of a 0.538 mmol/l albumin solution would be measured by employing an oncometer, a value of 9.2 mmHg would be actually measured. In plasma, however, the oncotic pressure is lower than that measured or theoretically computed, simply because, even in healthy subjects, the permeability of the endothelial barrier to albumin widely varies, depending on different organ systems (Table 1 ) [15, 16] . In diseased states, the altered capillary permeability nullifies the oncotic properties of albumin at different extent. Therefore, as suggested originally by Starling [17] , there are two forces within the capillary microcirculation acting in an opposite manner: the hydrostatic pressure, tending to push the 'solvent' out of the capillaries, and the oncotic pressure, tending to re-absorb the 'solvent' from the interstitial space into the capillaries. When the two pressures are equal, no water transfer occurs, whereas it may be positive (leading to interstitial fluid accumulation) in case of hydrostatic pressure greater than oncotic pressure, and vice versa. The classical Starling's view has been revised in the last 10 years, after the identification of the glycocalyx as a crucial structure regulating transvascular fluid exchange [18] . According to this paradigm, the impermeability to albumin occurs at the endothelial glycocalyx layer. Nonetheless, in our opinion, it does not modify essentially the Starling's concept, at least at the venular side. This is quite evident in full-blown sepsis, wherein the capillary permeability is altered at such extent that the amount of fluid given to achieve a predefined hemodynamic target is similar, whether including crystalloids, with or without albumin, or synthetic colloids [19 & ].
SECONDARY FUNCTIONS OF HUMAN ALBUMIN
Albumin has well-known physiological secondary properties [2] . Within its molecular structure, the thiol residues provide antioxidant properties, buffering the harmful actions of nitric oxide and free oxygen radicals [20, 21] , whereas the carboxyl terminals of histidine make albumin the most efficient buffering molecule of the extracellular acid-base equilibrium [22] . These functions are operative as long as the thiol and histidine groups are functionally active [23] . Otherwise, despite 'normal' plasma albumin concentration, these properties may be functionally inactive [24 & ]. Two novel secondary functions have been recently investigated. O'Brien et al. [25 & ], in an
KEY POINTS
Albumin is one of the main determinants of the integrity of the endothelial glycocalyx, thus cooperating in the maintenance of the intravascular compartment volume.
In decompensated cirrhosis, albumin may reverse immune-paralysis associated with prostaglandin E 2 release, and preserve myocardial contractility by blocking inducible nitric oxide synthase.
Although its administration in critically ill patients may have heterogeneous effects, human albumin administration may be advantageous in burn patients, whereas it may increase the risk of acute kidney injury in patients after cardiac surgery.
In severe sepsis, the ALBIOS trial did not show any survival benefit associated with albumin administration, while reporting a reduction in 90-day mortality in the subgroup of patients with septic shock, at post-hoc and not predefined analysis.
All the eight meta-analyses performed on the use of albumin in sepsis have shown no improvement in survival as associated with its administration in patients with sepsis or severe sepsis, while suggesting a beneficial effect in patients with shock, yet to be confirmed. extensive translational study, investigated the role of the cyclooxygenase-derived eicosanoid prostaglandin E 2 (PGE 2 ) as a mediator of the immunosuppressive state characterizing advanced cirrhosis. In their study, the authors observed that plasma of patients with acute decompensated liver cirrhosis had elevated circulating levels of PGE 2 , which are able to suppress the pro-inflammatory and the bacteria-killing capacity of macrophages. Albumin administration, by reducing circulating PGE 2 levels, significantly improved the plasma-induced impairment of macrophage pro-inflammatory actions, indicating that albumin-containing solutions may attenuate the PGE 2 -mediated immunosuppression and the associated risk of secondary infections. In another study, Bortoluzzi et al. [26] elucidated the effects of albumin on cardiac contractility in an experimental model of decompensated cirrhosis. The investigators observed that after the development of cirrhosis, cardiac contractility was impaired in association with an increased inducible nitricoxide synthase (iNOS) and TNF alpha protein expression. After administration of albumin, but not of synthetic colloids, these cellular alterations, in parallel with cardiac functionality, returned to normal levels, suggesting a potential for albumin acting as a positive inotropic agent by contrasting the effects of iNOS and TNF alpha-pathways. Although these findings relate to cirrhotic patients, their transferability to acutely critically ill patients may open possible novel therapeutic options of great potential.
ALBUMIN-CONTAINING SOLUTIONS AND EFFECTS ON ACID-BASE EQUILIBRIUM
According to Stewart's approach to acid-base equilibrium, pH is regulated by the strong ion difference (SID), defined as the difference between strong cations and anions, the partial pressure of carbon dioxide and the concentration of nonvolatile weak acids (mainly albumin and phosphates) [27] . Infusion of crystalloid solutions affects plasma pH according to the difference between plasma bicarbonate concentration (HCO 3 À ) and the SID of the infused crystalloid (SID INF ) [28, 29] . If SID INF is greater than baseline HCO 3 À concentration, pH will increase (generating alkalosis). If SID INF is lower than baseline HCO 3 À concentration, pH will decrease (generating acidosis). If SID INF approximates the baseline concentration of HCO 3 À , pH will eventually remain constant, regardless of the amount of the infusion, and the degree of dilution [30 && ]. Colloid solutions are, de facto, crystalloid solutions containing oncotic macromolecules.
Schematically, based upon their electrical characteristics, colloid molecules may be either characterized by a neutral activity, such as starches and dextrans, or by surface negative charges, such as gelatin and albumin [30 && ]. Consequently, starches and dextrans do not interfere with the electrochemical balance, and solutions containing starches and dextrans follow simple rules described for crystalloid solutions. On the contrary, gelatins and albumin have surface negative charges. Within the framework of Stewart's approach, these molecules belong to the category of weak acids, and therefore have per se an acidifying effect [30 && ]. Commercially available albumin solutions differ in electrolyte composition, mainly due to the specific purification process applied for human plasma and the preparation of solutions with different albumin concentration (mainly 4%, 5% and 20%), and, consequently, differ from endogenous albumin, in terms of half-life and antioxidant properties [31] . Most of studies performed describe, in fact, the development of mild metabolic acidosis after the infusion of albumin preparations [32,33 & ] , although this effect is primarily because of the specific electrolytic composition (i.e. the SID of the solvent), rather than the effect of the albumin molecule [34] .
ALBUMIN IN CRITICALLY ILL PATIENTS
Since the late 1940s [35] , intravenous solutions containing albumin have been extensively administered to critically ill patients, despite conflicting results on its effect on survival [36 && ]. Navickis et al. [37 & ] performed a meta-analysis on four randomized and four nonrandomized studies on burn shock resuscitation with albumin solutions. After the exclusion of two studies at high risk of bias, the authors observed a significant reduction in mortality and in incidence of abdominal compartment syndrome in patients receiving albumin. Despite such promising findings, the paucity of available data and the poor quality of RCTs warrant confirmatory studies. Similarly, in another meta-analysis, Kitsios et al. ] performed a meta-analysis to evaluate the impact on mortality and lung function of the use of either crystalloid or albumin-containing solutions in adult acute respiratory distress syndrome (ARDS). According to their analysis, pooled risk of death was equal between the two groups, whereas oxygenation appeared to be superior in patients receiving albumin. The authors interpret this finding as the result of a reduced alveolar-capillary leakage, although this effect did not translate in an improvement of survival. Lastly,
] performed a retrospective cohort study including patients undergoing onpump cardiac surgery to assess the risk of acute kidney injury (AKI) associated with either albumin or starches administration. The authors found albumin-containing solutions to be associated with a dose-dependent risk of AKI development. In the context of previous observational [41,42] and recent findings observed in the ALBIOS trial [12 && ], with no evidence of an increased risk of AKI even with the use of hyperoncotic albumin solutions, this issue merits further investigations.
ALBUMIN ADMINISTRATION IN SEPSIS: THE LARGE RANDOMIZED CONTROLLED TRIALS
Two large RCTs have investigated so far the efficacy of albumin administration in patients with severe sepsis or septic shock: the EARSS study (Early Albumin Resuscitation during Septic Shock), published only in form of an abstract [11] , and the ALBIOS trial (Albumin Italian Outcome Sepsis), published the last year [12 && ]. The EARSS trial (NCT00327704), a French multicenter, open-label RCT, enrolled 794 patients with early septic shock, randomized to receive either 20% albumin or isotonic saline for the first 3 days of fluid resuscitation. The authors reported no significant difference in mortality rates between the two groups (24.1% vs. 26.3%).
In the ALBIOS trial, we investigated the efficacy of albumin replacement, aimed at maintaining a targeted serum albumin level equal to or greater than 30 g/l, in addition to crystalloids during the first 28 days after randomization in patients with severe sepsis or septic shock, as compared with crystalloids alone [12 && ]. The study enrolled, from 100 Italian ICUs, 1818 patients within 24 h from the development of severe sepsis. Albumin administration in addition to crystalloids was associated with a higher mean arterial pressure and a lower net positive fluid balance over the first 7 days, as compared with the administration of crystalloids alone, despite a similar daily amount of total administered fluids. Nonetheless, at 90 days, mortality rates appeared similar between the two groups (41.1 vs. 43.6%, P ¼ 0.29, respectively), as were all the secondary outcomes assessed, with the exception of the time to suspension of vasoactive agents, being shorter in the albumin as compared with the crystalloid group. In contrast, in a post-hoc subgroup analysis on patients with shock at the time of enrolment, we observed a significant reduction in 90-day mortality rate in the albumin group as compared with the crystalloid group (N ¼ 1121, 43.6 vs. 49.9%, P ¼ 0.03). Taken together, these findings showed that albumin supplementation in addition to crystalloids to correct hypoalbuminemia does not improve 90-day survival in patients with severe sepsis, as compared with the use of crystalloids alone. In contrast, they suggest a possible benefit in the subgroup of patients with septic shock. As noted by 
ALBUMIN ADMINISTRATION IN SEPSIS: THE META-ANALYSES
Since the first meta-analysis on the use of albumin in patients with sepsis [45] , several meta-analyses have been added to this theme, especially after the conclusion of the ALBIOS trial ( ]. Of note, based upon data from essentially only two large-scale RCTs evaluating the efficacy of albumin administration in patients with sepsis [11,44 & ], already eight different meta-analyses have been published, of which five in the last year.
As a potential limitation of the meta-analytic methodology, the analyses performed differ in many aspects, most of them affecting study inclusion, and leading to the analysis of heterogeneous populations. First, the targeted population varies from patients with severe sepsis or septic shock [47, 48 & ,49 && ,52 & ], to those with sepsis of any severity, without predefined subgroup analysis [45, 46] . Moreover, some studies included both adult and pediatric patients [45,51 & ]. Second, the outcome measurements, and the time of its assessment, are variable between studies. Third, the treatment chosen for the comparison was often not homogeneous, including either the use of crystalloids ]. What can we derive from these data? Evidence gathered so far indicates that in a general population of patients with severe sepsis, the administration of albumin-containing solutions is not associated with a significant reduction in mortality rate (at least until the generally accepted follow-up time of 90 days), as suggested by the two large concluded RCTs [11,12 && ]. Of note, the analyses performed have always observed a relative risk variation in favor of the treatment with albumin, although not achieving (but being close to) a statistical significance. Such consistency of findings suggests, with a relatively high degree of certainty, that albumin administration to these patients does not cause harm, and that the beneficial effects related to it, if any, may be quantitatively smaller than expected. At the same time, the same evidence indicate that there might be a beneficial effect related to albumin in the subgroup of patients with septic shock, as observed also in the post-hoc analysis from the ALBIOS trial [12
&&

,44
& ], and that this hypothesis merits further confirmations. Such considerations gain even more importance when evaluating the potential cost-effectiveness of employing albumincontaining solutions in critically ill patients, and patients with severe sepsis or septic shock, because of their relative high cost. In fact, although as estimate, recent cost-effectiveness analyses have suggested that albumin administration may be the most cost-effective treatment, as compared with other colloids or crystalloids, in septic patients, when considering all the medical costs implied in patient clinical treatment [53] .
CONCLUSION
It is crucial to consider three further aspects, which raise still unanswered questions. First, as most of the evidence achieved so far has been focused on mortality as primary outcome, it is conceivable that secondary, and more physiological outcomes (such as organ functions) will unveil different effects, still clinically relevant, related to the use of albumin, albumin being one of the most important physiological extracellular proteins. Second, we still need ad-hoc clinical studies testing aspects so far still not investigated, such as the effects of different timing, doses and rationales for albumin administration [36 && ]. Third, based upon the wide variability of phenotypes originating by the syndrome 'sepsis,' it is possible that specific categories of patients will show a variability of effects related to albumin administration, and possibly at follow-up time longer than those assessed.
Is therefore albumin the ideal colloid for critically ill patients? With the exception of patients with traumatic brain injury [5] , ideally, the answer may be 'yes,' but, in practice, we have no solid clinical evidence for its cost-effective benefit, and, more importantly, many questions to be answered. Without being religiously believers of the benefit of albumin administration in acutely ill patients, or those with severe sepsis, we need to keep on studying its physiological mechanisms of action, in the attempt to individuate subgroups of patients, which may benefit, or may even receive harm, from this treatment. Based upon simple notions of physiology and the clinical evidence available, the premises are still promising.
